企業熱話｜G-NiiB夥大學推 腸道補充劑 提升新冠肺炎疫苗功效
A big thank you to Sing Tao Daily and Headline Daily for the excellent articles highlighting the importance of G-NiiB Immunity Formula and its remarkable ability to boost the efficacy of COVID-19 vaccines.
As a unique microbiome biotechnology startup in Hong Kong with a mission to transform novel microbiome signatures into ground-breaking diagnostics and effective therapeutics, our newly developed M3CRC, the world’s only non-invasive and high sensitivity colorectal cancer risk prediction test that detects non-advanced adenoma and adenoma recurrence at 94% and 90% sensitivity respectively, we are always grateful when the media highlight the impactful work we do.
It is our sincere hope that more people will become aware of the numerous health issues associated with gut dysbiosis, and how we can all improve our gut health by repairing the intestinal microbiome in our bodies. As our CEO Rachel Fan said in the media interview, “We cannot change our genes, but we can affect our gut microbiome to improve our health.”
